The Immune Response Corporation

The Immune Response Corporation (OTCBB: IMNR.OB) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company’s lead immune-based therapeutic product candidates are NeuroVax™ for the treatment of MS and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax™, which is based on the Company’s patented T-cell receptor (TCR) peptide technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax™ has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down-regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn’s disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis

Contact Details: 5931 Darwin Court Carlsbad California 92008 United States of America Tel: 760-431-7080 Fax: 760-431-8636 Email: WWW: www.imnr.com/

Loading...

Recent Publications by The Immune Response Corporation:
Identification of reciprocally regulated gene modules in regenerating dorsal root ganglion neurons and activated peripheral or central nervous system glia. Differential gene expression in the rat after injury of dorsal root...	3rd December, 2003	The Immune Response Corporation, 5935 Darwin Court, Carlsbad, California	J Cell Biochem. 2003 Apr 1;88(5):970-85. DOI Direct Link
HIV-specific immunity during structured antiviral drug treatment interruption. The immunologic correlates associated with control of viremia in HIV...	1st November, 2003	The Immune Response Corporation, 5935 Darwin Court, Carlsbad, CA 92008,	Vaccine. 2003 Mar 7;21(11-12):1066-71.
Propofol phosphate, a water-soluble propofol prodrug: in vivo evaluation. After a single IV injection of the water-soluble propofol prodrug propofol...	26th November, 2002	Chemistry Department, The Immune Response Corporation, 5935 Darwin Court,	Anesth Analg. 2002 Nov;95(5):1285-92, table of contents.
Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine. Cancer vaccines composed of tumor cells engineered to secrete...	18th October, 2002	Division of Cancer, The Immune Response Corporation, 5935 Darwin Court,	Gene Ther. 2002 Oct;9(19):1302-11. DOI Direct Link
Maternal and newborn immunization with a human immunodeficiency virus-1 immunogen in a rodent model. We examined immunization with an inactivated, gp120-depleted human...	3rd October, 2002	The Immune Response Corporation, Carlsbad, California 92008, USA.	Immunology. 2002 Aug;106(4):549-53.
→View more The Immune Response Corporation research publications.

BioNews Results for The Immune Response Corporation:
Hemispherx to Present Data At 'Second World Conference On Magic Bullets (Erlich II)'	Therapeutics Daily:  Sep 30 2008 2:33PM Matching: immune response
Hemispherx to Present Data At 'Second World Conference On Magic Bullets (Erlich II)'	Yahoo!:  Sep 30 2008 1:35PM Matching: immune response
Flu Vaccine Delivered Into Lungs Triggers Stronger Immune Response	Impact Lab:  Sep 25 2008 5:38PM Matching: immune response
Chemically programmable immunity	PharmCast:  Sep 23 2008 12:15PM Matching: immune response
Sub-Analysis of Phase III Study Suggests More than Single Treatment may be Required for Therapeutic Response i	DiGiTAL50:  Sep 23 2008 6:40PM Matching: immune response
Promote your company here: BioNewsCast - Press Release Distribution	→View more The Immune Response Corporation news.

The Immune Response Corporation Patents:
US Patent No.	Title
6737066	HIV immunogenic compositions and methods
5985552	Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
5916806	Prevention and treatment of retroviral disease
5895650	Prevention and treatment of retroviral disease
5891432	Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
→View more The Immune Response Corporation patents.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 241 times since April 2007, the link to the organisation's website has been followed 53 times

Recent Search Terms used to find this page: The Immune Response Corporation 5931 Darwin Court | Immune Response Corporation | The Immune Response Corporation 5931 Darwin Court | immune response corp | 5931 Darwin Court, Carlsbad, California | The Immune Response Corporation Carlsbad Ca 2008 | immune response corporation | immune response corporation | .

Search for more companies in Carlsbad

Search for more companies in California

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for The Immune Response Corporation